NOVO NORDISK A S NVO

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $44.02
Market Cap $147.29B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑6.4% YoY
$309.06B
3-Yr CAGR: 20.4%
Net Income ↑2.6% YoY
$130.54B
Net Margin: 42.2%
Free Cash Flow ↓-60.5% YoY
-$28.13B
FCF Yield: -19.10%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
67.3%
ROA: 24.0%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVO)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $111,780.0M $94,597.0M $47,798.0M 0.00% $2,899.0M
FY 2017 $111,696.0M -0.1% $94,064.0M $48,680.0M +1.8% 0.00% $9,101.0M $1,475.0M
FY 2018 $111,831.0M +0.1% $94,214.0M $47,615.0M -2.2% 0.00% $9,614.0M $-22.0M -101.5%
FY 2019 $122,021.0M +9.1% $101,933.0M $48,553.0M +2.0% 0.00% $10,936.0M $2,004.0M +9,209.1%
FY 2020 $126,946.0M +4.0% $106,014.0M $53,130.0M +9.4% 0.00% $10,106.0M $4,281.0M +113.6%
FY 2021 $140,800.0M +10.9% $117,142.0M $59,080.0M +11.2% 0.00% $14,438.0M $8,103.0M +89.3%
FY 2022 $176,954.0M +25.7% $148,506.0M $69,062.0M +16.9% 0.00% $14,515.0M $2,369.0M -70.8%
FY 2023 $232,261.0M +31.3% $196,496.0M $104,674.0M +51.6% 0.00% $25,897.0M $91.0M -96.2%
FY 2024 $290,403.0M +25.0% $245,881.0M $127,191.0M +21.5% 0.00% $29,636.0M $-17,528.0M -19,361.5%
FY 2025 $309,064.0M +6.4% $250,276.0M $130,540.0M +2.6% 0.00% $32,014.0M $-28,126.0M -60.5%
$

Valuation

Market Price $44.02
Market Cap $147.29B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio 0.76
FCF Yield -19.10%
Dividend Yield 0.00%
Shares Outstanding 3,345,878,500
%

Profitability & Margins

Gross Margin 80.98%
Operating Margin 41.30%
Net Margin 42.24%
Return on Equity (ROE) 67.27%
Return on Assets (ROA) 24.04%
Asset Turnover 0.57x
Revenue 3-Yr CAGR 20.43%
🛡️

Financial Health & Liquidity

Current Ratio 0.58
Cash Ratio N/A
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share $58.00
💧

Cash Flow Efficiency

Operating Cash Flow $32.01B
Capital Expenditures (CapEx) $60.14B
Free Cash Flow -$28.13B
OCF / Revenue 10.36%
FCF / Revenue -9.10%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $58.00
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $542.90B
Total Liabilities $348.86B
Stockholders' Equity $194.05B
Current Assets $4.85B
Current Liabilities $8.42B